Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
KM Biologics, a Meiji group company, has acquired an exclusive option to French biopharma Osivax’s broad-spectrum universal influenza vaccine candidates in Japan, the two companies said on September 10. Under their pact, KM Biologics holds an exclusive option to exercise…
To read the full story
Related Article
- Meiji Invests in French Vaccine Player Osivax
March 5, 2025
BUSINESS
- Tanabe to Wind Down NeuroDerm, Scrap EU Launch of Parkinson’s Drug
November 19, 2026
- Shionogi Narrows R&D Pipeline to 21 Priority Programs Across 3 Disease Areas
November 19, 2026
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026





